Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 7/2016

01-07-2016 | Breast

Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel 1H-magnetic resonance spectroscopy and 18F-fluorodeoxyglucose positron emission tomography

Authors: Nariya Cho, Seock-Ah Im, Keon Wook Kang, In-Ae Park, In Chan Song, Kyung-Hun Lee, Tae-Yong Kim, Hyunjong Lee, In Kook Chun, Hai-Jeon Yoon, Woo Kyung Moon

Published in: European Radiology | Issue 7/2016

Login to get access

Abstract

Objectives

To prospectively compare performances of single-voxel proton magnetic resonance spectroscopy (1H-MRS) and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in predicting pathologic response to neoadjuvant chemotherapy (NAC) in breast cancer patients.

Methods

Thirty-five breast cancer patients who received NAC and subsequent surgery were prospectively enrolled. MRS and FDG-PET were performed before and after the 1st NAC cycle. Percentage changes of total choline-containing compounds (tCho) via MRS, and maximum and peak standardized uptake values (SUVmax, SUVpeak) and total lesion glycolysis (TLG) via FDG-PET were measured, and their performances in predicting pathologic complete response (pCR) were compared.

Results

Of the 35 patients, 6 showed pCR and 29 showed non-pCR. Mean % reductions of tCho, SUVmax, SUVpeak, and TLG of the pCR group were larger than those of the non-pCR group (-80.3 ± 13.9 % vs. -32.1 ± 49.4 %, P = 0.025; -54.7 ± 22.1 % vs. -26.3 ± 33.7 %, P = 0.058; -60.7 ± 18.3 % vs. -32.3 ± 23.3 %, P = 0.009; -89.5 ± 8.5 % vs. -52.6 ± 36.2 %, P = 0.020). Diagnostic accuracy (area under ROC curve; Az, 0.911) of the % reduction of tCho was comparable to those of %SUVmax (0.822), SUVpeak (0.862), and TLG (0.879) in distinguishing pCR from non-pCR (all P > 0.05).

Conclusion

MRS showed comparable performance to FDG-PET in early prediction of pCR in breast cancer patients.

Key points

• MRS can predict response to NAC in breast cancer post-1 st cycle.
• Changes in tCho and SUV after NAC reflect tumour cellularity changes.
• MRS can be an alternative to FDG-PET in predicting response to NAC.
Literature
1.
Chia S, Swain SM, Byrd DR et al (2008) Locally advanced and inflammatory breast cancer. J Clin Oncol 26:786–790CrossRefPubMed
2.
Buchholz TA, Lehman CD, Harris JR et al (2008) Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute Conference. J Clin Oncol 26:791–797CrossRefPubMed
3.
Von Minckwitz G, Kaufmann M, Kuemmel S, for the GBG and AGO-B Study Groups et al (2011) Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: results from the German neoadjuvant meta-analysis. J Clin Oncol 29:1028
4.
Kaufmann M, von Minckwitz G, Mamounas EP et al (2012) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19:1508–1516CrossRefPubMed
5.
von Minckwitz G, Blohmer JU, Costa SD et al (2013) Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 31:3623–3630CrossRef
6.
Hylton NM, Blume JD, Bernreuter WK et al (2012) Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology 263:663–672CrossRefPubMedPubMedCentral
7.
Rieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R, Kuhn T (2002) Breast MRI for monitoring response of primary breast cancer to neoadjuvant chemotherapy. Eur Radiol 12:1711–1719CrossRefPubMed
8.
Rousseau C, Devillers A, Sagan C et al (2006) Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 24:5366–5372CrossRefPubMed
9.
Schwarz-Dose J, Untch M, Tiling R et al (2009) Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 27:535–541CrossRefPubMed
10.
Meisamy S, Bolan PJ, Baker EH et al (2004) Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T. Radiology 233:424–431CrossRefPubMed
11.
Baek HM, Chen JH, Nie K et al (2009) Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology 251:653–662CrossRefPubMedPubMedCentral
12.
Danishad KKA, Sharma U, Sah RG, Seenu V, Parshad R, Jagannathan NR (2010) Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI). NMR Biomed 23:233–241PubMed
13.
Tozaki M, Sakamoto M, Oyama Y et al (2008) Monitoring of early response to neoadjuvant chemotherapy in breast cancer with (1)H MR spectroscopy: comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography. J Magn Reson Imaging 28:420–427CrossRefPubMed
14.
Cho N, Im SA, Park IA et al (2014) Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging. Radiology 272:385–396CrossRefPubMed
15.
Tozaki M, Sakamoto M, Oyama Y, Maruyama K, Fukuma E (2010) Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1H MR spectroscopy using the external standard method. J Magn Reson Imaging 31:895–902CrossRefPubMed
16.
Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150SCrossRefPubMedPubMedCentral
17.
Lopci E, Zucali PA, Ceresoli GL et al (2015) Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. Eur J Nucl Med Mol Imaging 42:667–675CrossRefPubMed
18.
Im HJ, Kim YK, Kim YI, Lee JJ, Lee WW, Kim SE (2013) Usefulness of combined metabolic-volumetric indices of (18)F-FDG PET/CT for the early prediction of neoadjuvant chemotherapy outcomes in breast cancer. Nucl Med Mol Imaging 47:36–43CrossRefPubMed
19.
Ogston KN, Miller ID, Payne S et al (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12:320–327CrossRefPubMed
20.
21.
Jung SY, Kim SK, Nam BH et al (2010) Prognostic impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy. Ann Surg Oncol 17:247–253CrossRefPubMed
22.
Connolly RM, Leal JP, Goetz MP et al (2015) TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer. J Nucl Med 56:31–37CrossRefPubMed
23.
Ah-See ML, Makris A, Taylor NJ et al (2008) Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 14:6580–6589CrossRefPubMed
24.
Li SP, Makris A, Beresford MJ et al (2011) Use of dynamic contrast-enhanced MR Imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy. Radiology 260:68–78CrossRefPubMed
25.
Tateishi U, Miyake M, Nagaoka T et al (2012) Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment. Radiology 263:53–63CrossRefPubMed
26.
Pengel KE, Koolen BB, Loo CE et al (2014) Combined use of 18F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 41:1515–1524CrossRefPubMed
27.
Lim I, Noh WC, Park J et al (2014) The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 41:1852–1860CrossRefPubMed
28.
An YY, Kim SH, Kang BJ, Lee AW (2015) Treatment response evaluation of breast cancer after neoadjuvant chemotherapy and usefulness of the imaging parameters of MRI and PET/CT. J Korean Med Sci 30:808–815CrossRefPubMedPubMedCentral
29.
Aboagye EO, Bhujwalla ZM (1999) Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 59:80–84PubMed
30.
31.
Kolesnikov-Gauthier H, Vanlemmens L, Baranzelli MC et al (2012) Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course. Breast Cancer Res Treat 131:517–525CrossRefPubMed
32.
Young H, Baum R, Cremerius U et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773–1782CrossRefPubMed
33.
Begley JK, Redpath TW, Bolan PJ, Gilbert FJ (2012) In vivo proton magnetic resonance spectroscopy of breast cancer: a review of the literature. Breast Cancer Res 14:207
34.
Sardanelli F, Fausto A, Di Leo G, de Nijs R, Vorbuchner M, Podo F (2009) In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy. AJR Am J Roentgenol 192:1608–1617CrossRefPubMed
Metadata
Title
Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel 1H-magnetic resonance spectroscopy and 18F-fluorodeoxyglucose positron emission tomography
Authors
Nariya Cho
Seock-Ah Im
Keon Wook Kang
In-Ae Park
In Chan Song
Kyung-Hun Lee
Tae-Yong Kim
Hyunjong Lee
In Kook Chun
Hai-Jeon Yoon
Woo Kyung Moon
Publication date
01-07-2016
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 7/2016
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-015-4014-7

Other articles of this Issue 7/2016

European Radiology 7/2016 Go to the issue

Computed Tomography

How often are Patients Harmed When They Visit the Computed Tomography Suite? A Multi-year Experience, in Incident Reporting, in a Large Academic Medical Center

Gastrointestinal

Monitoring Crohn’s disease during anti-TNF-α therapy: validation of the magnetic resonance enterography global score (MEGS) against a combined clinical reference standard

Breast

Is there a systematic bias of apparent diffusion coefficient (ADC) measurements of the breast if measured on different workstations? An inter- and intra-reader agreement study

Computed Tomography

Comparison of the image qualities of filtered back-projection, adaptive statistical iterative reconstruction, and model-based iterative reconstruction for CT venography at 80 kVp

Oncology

Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study

Ultrasound

Assessment of liver fibrosis in chronic hepatitis B using acoustic structure quantification: quantitative morphological ultrasound